Огляд
Select a topic to solve related cases or follow a course topic
-
Topic 1Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 2Adjuvant therapy in RCC
-
Topic 3Finding the right ADT for the right patient
-
Topic 4Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 5High-risk non-metastatic prostate cancer
-
Topic 6NEW --- Sequencing treatments in mCRPC patients without HRR gene mutations
-
Topic 7NEW --- Treatment selection in mCRPC patients harbouring HRR gene mutations
-
Topic 8Management of non-metastatic castration-resistant prostate cancer
-
Topic 9High-risk non-metastatic prostate cancer
-
Topic 10Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 11Finding the right ADT for the right patient
-
Topic 12CDK4/6 inhibitors for everyone? First-line treatment strategies in HR+ HER2- MBC
-
Topic 13Progression after CDK4/6i + ET for HR+ HER2- MBC. What now?
-
Topic 14New hope for patients progressing after prior treatment for mUCa
-
Topic 15Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 16Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 17Initial treatment of MIBC
-
Topic 18Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 19Adjuvant treatment approaches for MIBC
-
Topic 20Molecular diagnostics in the era of targeted therapies for mUCa
-
Topic 21Handling AEs of targeted therapies for metastatic UCa
-
Topic 22First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 23Targeted therapies for metastatic UCa in special populations
-
Topic 24NEW --- Treatment approaches for patients diagnosed with (very) high-risk NMIBC
-
Topic 25Management of BCG-pretreated (very) high-risk NMIBC
-
Topic 26Systemic therapy for HER2-positive early breast cancer
-
Topic 27First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 28Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 29Systemic therapy for mRCC: second line and beyond
-
Topic 30Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 31Management of small renal masses
-
Topic 32Systemic therapy for early stage TNBC
-
Topic 33Local therapy for mRCC
-
Topic 34Radiotherapy for early breast cancer
-
Topic 35Management of HER2+ MBC
-
Topic 36Brain metastases in patients with HER2+ breast cancer
-
Topic 37Theragnostic testing – choosing the right therapy in mTNBC